Clinical trials: Respiratory Virus Infection
Premature Infants
Compliance to Synagis (Palivizumab) Under Daily Pediatrician´s Conditions in Premature Infants 33 - 35 wGA
Compliance to Synagis (palivizumab) is a key factor to obtain maximal protection against respiratory syncytial virus (RSV) infection as shown in the IMpact study.
- Trial name
- NCT01077271
- Where
- 45 sites in Austria
- Volunteers
- 124 people
- Sponsor
- Abbott
COVID-19
Effect of Daily Oral Administration of Food Supplement NLC-V in Patients Diagnosed With COVID-19
This study is designed to evaluate the safety and efficacy of NLC-V in patients diagnosed with COVID-19.
- Trial name
- NCT05226767
- Testing
- NLC-V
- Where
- Israel
- Volunteers
- 31 people
- Sponsor
- Todos Medical, Ltd.
Influenza
Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older
This clinical trial aims to study the immunogenicity of GSK Biologicals' influenza vaccine GSK2186877A in people aged 65 years or older.
- Trial name
- NCT00765076
- Testing
- GSK Biologicals' influenza vaccine GSK2186877A, GSK Biologicals' Fluarix
- Where
- 4 sites in United States, Spain
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL
This is a phase 2/3, multicenter, randomized, placebo-controlled, observer-blind study assessing the safety, tolerability, immunogenicity, and efficacy of prophylactic hAd5-S-Fusion+N-ETSD against COVID-19.
- Trial name
- NCT06022224
- Testing
- hAd5-S-Fusion+N-ETSD
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
Influenza
Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age
The purpose of this study is to characterize the safety and efficacy of GSK Biologicals' H1N1 flu candidate vaccines GSK2340274A and GSK2340273A in children 6 months to less than 10 years of age.
- Trial name
- NCT01051661
- Testing
- GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations), GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)
- Where
- 17 sites in Australia, Brazil and 6 more
- Volunteers
- 6,154 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Vaccine
A Study to Assess the Safety of ASP7374 in Adult Subjects Aged 20 or Older
The purpose of this study is to confirm the safety until Day 29 after injection of a single dose of quadrivalent vaccine ASP7374 in adult subjects aged 20 or older
- Trial name
- NCT02366962
- Testing
- ASP7374
- Where
- Japan
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- UMN Pharma Inc.
COVID-19
JINZHEN for Treatment of Mild to Moderate COVID-19
JINZHEN is a botanical drug that contains eight chemical constituents extracted from plant, mineral and animal origin raw materials.
- Trial name
- NCT05092503
- Testing
- JINZHEN Granules for Oral Solution
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Lianyungang Kanion Group, Ltd.
Influenza
Phase IV Trial to Collect Safety Data and Sera in Healthy Children Given Fluzone Vaccine
To provide serum to the Food and Drug Administration (FDA) for use by FDA, the Centers for Disease Control and Prevention (CDC), and the World Health Organization (WHO) for characterization of circulating influenza strains.
- Trial name
- NCT00258817
- Testing
- Influenza Virus Vaccine (Fluzone®)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Vaccine
A Study to Evaluate Intramuscular ASP7374
The purpose of this study is to evaluate safety and immunogenicity of intramuscular ASP7374 in adults ≥61 years of age.
- Trial name
- NCT01961960
- Testing
- ASP7374
- Where
- Japan
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- UMN Pharma Inc.
COVID-19
Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey
This is a randomized, double-blinded, and positive-controlled Phase IIb clinical trial of COVID-19 vaccine (CoronaVac®) manufactured by Sinovac Research \& Development Co., Ltd.The purpose of this study is to evaluate the…
- Trial name
- NCT05150496
- Testing
- Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated, High-dose COVID-19 Vaccine(Vero Cell),Inactivated
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
Influenza
Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects
The purpose of this study is to evaluate the safety and pharmacokinetic profile of flufirvitide-3 nasal spray in healthy subjects.
- Trial name
- NCT01313962
- Testing
- Flufirvitide-3 0.05 mg single dose, Flufirvitide-3, 0.1 mg single dose, Flufirvitide-3, 0.2 mg single dose
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Autoimmune Technologies, LLC
SARS-CoV-2
Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants
The study evaluated the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in infants aged 12 weeks to < 6 months.
- Trial name
- BabyCOVE (NCT05584202)
- Testing
- mRNA-1273.214
- Where
- 39 sites in United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Covid19
Study to Evaluate the Effects of Tempol (MBM-02) in COVID-19 Patients.
An Adaptive, Randomized, Double-blind, Placebo-controlled study to examine the Effects of Tempol in subjects with COVID-19 infection.
- Trial name
- NCT04729595
- Testing
- Tempol
- Where
- 17 sites in United States
- Volunteers
- 248 people
- Sponsor
- Adamis Pharmaceuticals Corporation
Coronavirus Disease 2019(COVID-19)
Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects
The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics of SCTA01(anti-SARS-CoV-2 monoclonal antibody) in Healthy Chinese Subjects.
- Trial name
- NCT04483375
- Testing
- SCTA01
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19
Immunogenicity and Safety Study of Monovalent Omicron XBB.1.5 Vaccine as a Booster in Adults
The purpose of this study is to assess the immunogenicity and safety of SCB-2023B monovalent Omicron XBB.1.5 vaccine compared to the prototype SCB-2019 vaccine in participants previously vaccinated with 3 doses of inactivated…
- Trial name
- NCT06567457
- Testing
- SCB-2023B vaccine, a monovalent Omicron XBB.1.5 recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19, SCB-2019 vaccine, a monovalent wu-hu1 SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19
- Volunteers
- healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Severe COVID-19 Pneumonia
A Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects With Severe Corona Virus Disease 2019（COVID-19）Pneumonia
The study is a Randomized, Open-Label, Multi-Centre, Phase 2a Study to Evaluate the Safety and Effect of STC3141 Continuous Infusion in Subjects with Severe Corona Virus Disease 2019（COVID-19）Pneumonia.
- Trial name
- NCT04880694
- Testing
- STC3141
- Where
- 4 sites in Belgium
- Volunteers
- 25 people
- Sponsor
- Grand Medical Pty Ltd.
RSV Infection, hMPV
Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years
VAV00039 is a first-in-human (FiH) study to assess the safety and immunogenicity (in adult participants aged 60-75 years) after a single injection of different dose formulations of an RSV/hMPV vaccine candidate and RSV vaccine.
- Trial name
- NCT06583031
- Testing
- RSV/hMPV vaccine dose A1, RSV/hMPV vaccine dose A2, RSV/hMPV vaccine dose A3
- Where
- 6 sites in Australia
- Volunteers
- 385 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Respiratory Syncytial Virus (RSV)
Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic Cosmos
Among non-pregnant adults observed in Epic Cosmos since August 2023 who are eligible for RSV vaccination, what is the effectiveness of ABRYSVO® (RSVpreF), compared with unvaccinated individuals, in preventing RSV-related and…
- Trial name
- NCT07673081
- Where
- United States
- Volunteers
- 293,334 people
- Sponsor
- Pfizer
COVID-19
Effectiveness of the Oxford-AstraZeneca COVID-19 Vaccine as a 2nd Booster, the REFORCO-Brazil Study
This study will address specific questions concerning the additional protection of the AZ COVID-19 vaccine as a second booster dose in preventing severe COVID-19 outcomes (hospitalisation, ICU admission etc) and will provide data…
- Trial name
- REFORCO-B (NCT05697705)
- Testing
- ChAdOx1 nCOV-19 vaccine (Vaxzeria), BNT162b2 (Pfizer), Ad26.COV2.S (Janssen)
- Where
- Brazil
- Volunteers
- 188,814,085 people
- Sponsor
- AstraZeneca
COVID-19
Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
This is an open-label Phase 3 study evaluating the immunogenicity and safety of Novavax vaccine(s) with Matrix-M™ adjuvant (ancestral strain NVX-CoV2373 and an alternative strain and/or multivalent Novavax vaccine) as booster…
- Trial name
- NCT05875701
- Testing
- NVX-CoV2373, SARS-CoV-2 rS antigen/Matrix-M Adjuvant
- Where
- 5 sites in United States
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Novavax
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.